The Parkinson Study Group   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1986)

Organization Overview

First Clinical Trial
2000
NCT00203034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

nicotine (nicorette) (1 trial)

Drugs in Phase 3 Trials (4)

cep-1347 (1 trial)

inosine (2 trials)

isradipine (dynacirc) (2 trials)

rasagiline (azilect) (1 trial)

Drugs in Phase 2 Trials (1)

conjugated equine estrogens (Premarin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Impulsive Behavior (Phase 4)

Parkinson Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 6